强化降压与脑出血点征:一项随机临床试验的二次分析
SCORE-IT为嵌套于ATACH-II随机临床试验的前瞻性观察研究,纳入133例发病8小时内完成CTA的原发性脑出血患者。点征预测血肿扩大的敏感度0.54、特异度0.63,低于既往单中心报告;在点征阳性患者中,强化降压未显著减少血肿扩大或改善90天结局。
要点
- 点征预测血肿扩大的敏感度0.54、特异度0.63,低于既往单中心研究。
- 点征阳性患者中强化降压未显著减少血肿扩大(RR 0.83,P=0.74)。
核心结论
- 点征对血肿扩大的预测效能低于既往单中心报告。
- 无证据表明伴点征的脑出血患者能从强化降压中特异获益。
研究设计与样本
- SCORE-IT为预先计划的前瞻性观察研究,嵌套于ATACH-II随机临床试验。
- 纳入59个中心连续的原发性脑出血患者,发病8小时内完成CTA,2011年5月15日至2015年12月19日入组。
- 共分析133例患者,男83例(62.4%)、女50例(37.6%),平均年龄61.9(SD 13.1)岁。
主要发现
- 53例(39.8%)存在点征;无缺失数据的123例中24例(19.5%)发生血肿扩大。
- 点征预测血肿扩大的敏感度0.54(95%CI 0.34-0.74),特异度0.63(95%CI 0.53-0.72)。
- 点征阳性患者中,强化降压与血肿扩大减少无显著关联(RR 0.83,95%CI 0.27-2.51,P=0.74)。
关键数值与推荐
- 强化降压目标为收缩压<140 mm Hg,标准降压目标为收缩压<180 mm Hg,均于发病4.5小时内开始。
- 血肿扩大定义为血肿体积增长大于33%。
- 不良结局定义为90天改良Rankin量表评分≥4分(范围0-6)。
临床怎么用
- 点征不应单独作为筛选强化降压获益患者的可靠依据。
- 对伴点征的脑出血患者,强化降压策略需结合其他临床与影像因素综合评估。
局限性
- 点征预测效能低于既往单中心研究,提示外推需谨慎。
- 点征阳性亚组样本量有限,强化降压相关估计的置信区间较宽。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The computed tomographic angiography (CTA) spot sign is associated with intracerebral hemorrhage (ICH) expansion and may mark those patients most likely to benefit from intensive blood pressure (BP) reduction. OBJECTIVE: To investigate whether the spot sign is associated with ICH expansion across a wide range of centers and whether intensive BP reduction decreases hematoma expansion and improves outcome in patients with ICH and a spot sign. DESIGN, SETTING, AND PARTICIPANTS: SCORE-IT (Spot Sign Score in Restricting ICH Growth) is a preplanned prospective observational study nested in the Antihypertensive Treatment of Acute Cerebral Hemorrhage II (ATACH-II) randomized clinical trial. Participants included consecutive patients with primary ICH who underwent a CTA within 8 hours from onset at 59 sites from May 15, 2011, through December 19, 2015. Data were analyzed for the present study from July 1 to August 31, 2016. MAIN OUTCOMES AND MEASURES: Patients in ATACH-II were randomized to intensive (systolic BP target, <140 mm Hg) vs standard (systolic BP target, <180 mm Hg) BP reduction within 4.5 hours from onset. Expansion of ICH was defined as hematoma growth of greater than 33%, and an unfavorable outcome was defined as a 90-day modified Rankin Scale score of 4 or greater (range, 0-6). The association among BP reduction, ICH expansion, and outcome was investigated with multivariable logistic regression. RESULTS: A total of 133 patients (83 men [62.4%] and 50 women [37.6%]; mean [SD] age, 61.9 [13.1] years) were included. Of these, 53 (39.8%) had a spot sign, and 24 of 123 without missing data (19.5%) experienced ICH expansion. The spot sign was associated with expansion with sensitivity of 0.54 (95% CI, 0.34-0.74) and specificity of 0.63 (95% CI, 0.53-0.72). After adjustment for potential confounders, intensive BP treatment was not associated with a significant reduction of ICH expansion (relative risk, 0.83; 95% CI, 0.27-2.51; P = .74) or improved outcome (relative risk of 90-day modified Rankin Scale score ≥4, 1.24; 95% CI, 0.53-2.91; P = .62) in spot sign-positive patients. CONCLUSIONS AND RELEVANCE: The predictive performance of the spot sign for ICH expansion was lower than in prior reports from single-center studies. No evidence suggested that patients with ICH and a spot sign specifically benefit from intensive BP reduction. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01176565.
引用
- Morotti A, Brouwers HB, Romero JM, et al. Intensive Blood Pressure Reduction and Spot Sign in Intracerebral Hemorrhage: A Secondary Analysis of a Randomized Clinical Trial. JAMA Neurol. 2017. PMID: 28628707. doi:10.1001/jamaneurol.2017.1014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。